SCHEMBL5584260

SCHEMBL5584260

COCOc1cccc2sccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.36
F2RL3 Q96RI0 2/20 0.34
HTR1A P08908 2/20 0.34
DRD2 P14416 2/20 0.34
HTR2A P28223 2/20 0.34
EPAS1 Q99814 2/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
P2RX7 Q99572 1/20 0.33
MEN1 O00255 1/20 0.33
TNF P01375 1/20 0.33
KMT2A Q03164 1/20 0.33
NOD1 Q9Y239 1/20 0.33
CYP19A1 P11511 1/20 0.33
TBXAS1 P24557 1/20 0.33
VEGFA P15692 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827357 0.82 ALDH1A1 (0.45) DRD2MEN1KMT2A
SCHEMBL827010 0.80 CA2 (0.44) HTR1ADRD2HTR2AADRA2AADRA2B
SCHEMBL3791996 0.79 CYP2A6 (0.45) MEN1KMT2ACYP1A2CYP2C19
SCHEMBL20562457 0.78 MAPT (0.35) PTPN1
SCHEMBL3797699 0.78 CYP1A2 (0.46) CYP19A1SLC6A4CYP1A2CYP2C19
SCHEMBL914916 0.78 NR2E1 (0.37) HTR1AHTR2AADRA2AMEN1KMT2A
SCHEMBL20563185 0.77 HTR2C (0.31) SMN1; SMN2
SCHEMBL20563888 0.77 KEAP1 (0.32) MRGPRX1
SCHEMBL28744577 0.75 CA2 (0.44) HTR1ADRD2HTR2AP2RX7
SCHEMBL17274813 0.75 CYP3A4 (0.47) EPAS1ADRA2AADRA2BCYP19A1TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A PTPN1 854/4885F2RL3 3870/4885HTR1A 1/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A PTPN1 854/4885F2RL3 3870/4885HTR1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.